Introduction {#sec1}
============

Hepatocellular carcinoma (HCC) is the third major cause of cancer-related deaths and caused approximately over 700000 deaths worldwide each year \[[@B1]\]. It is reported that HCC in China alone accounts for \>50% of the cases worldwide owing to the prevalence of hepatitis B virus (HBV)-induced hepatitis \[[@B4]\]. Despite the improvement in technology, most HCC patients continue to be diagnosed at advanced stage and the 5-year survival rate is still below 20% \[[@B5]\]. Epidemiologic evidence indicates that during the next decades the burden caused by HCC will still significantly increase \[[@B6]\]. At present, plasma α-fetoprotein (AFP) has been widely used in clinical practice, however, the utility of AFP is limited due to its low sensitivity and specificity \[[@B7]\]. Therefore, it is urgently needed to identify new tumor markers with high sensitivity and specificity to detect HCC independently or as a supplement of AFP.

Long non-coding RNAs (lncRNAs) are a group of RNAs longer than 200 nts in length which have no protein-coding potential \[[@B8]\]. LncRNAs can regulate gene expression at transcriptional, post-transcriptional, and epigenetic levels, and play critical roles in multiple biological processes across every branch of life such as cell growth, differentiation, proliferation, survival, and migration \[[@B9]\]. Notably, emerging evidences have pointed out that dysregulation of lncRNAs can contribute to the progress of various human diseases, especially cancer \[[@B10]\]. Abundant recent research suggests that lncRNAs play critical roles in the initiation and progression of HCC. For instance, up-regulation of lncRNA *LOC90784* can promote cell invasion and proliferation and is associated with poor clinical features in HCC \[[@B11]\]. Furthermore, it is reported that plasma DANCR showed an increased discriminatory power for differentiating HCC patients from non-HCC patients compared with AFP \[[@B12]\]. Therefore, we highly hold the view that lncRNAs can be potential diagnostic markers for HCC.

Clinical biomarkers should be easily accessible and non-invasive. Circulating RNA in plasma or serum has attracted wide attention for its non-invasive feature \[[@B13]\]. Increasing number of studies has demonstrated that circulating lncRNAs have dysregulated in plasma or serum, indicating their high potential as powerful and non-invasive tumor markers \[[@B14],[@B15]\]. For example, *H19* was found to be significantly up-regulated in plasma of gastric cancer patients, and could be used to discriminate gastric cancer patients from healthy controls \[[@B16]\]. LncRNA *POU3F3* could serve as a potential biomarker to diagnose esophageal squamous cell carcinoma \[[@B17]\]. In breast cancer patients, *GAS5* can be used as a potential biomarker to assess the surgical effects \[[@B18]\]. However, few studies investigated circulating lncRNA for early detection of HCC patients.

Here we selected six candidate cancer-related lncRNAs (*ZFAS1* \[[@B19]\], *PRNCR1* \[[@B20]\], *GAS5* \[[@B21]\], *TUG1* \[[@B22]\], *linc-ROR* \[[@B23]\], and *H19* \[[@B24]\]) through articles that were previously reported to be dysregulated in cancer. The aim of our study was to validate whether the lncRNAs we selected were detectable and altered in HCC patients, then to find out whether it is a suitable biomarker to diagnose HCC.

Materials and methods {#sec2}
=====================

Sample collection {#sec2-1}
-----------------

Twenty-two paired fresh tumor tissues and adjacent normal tissues were obtained from HCC patients who underwent surgical resection in Zhongnan Hospital of Wuhan University between January and July 2016. All the tissues were immediately stored at −80°C until RNA extraction. Blood samples from 80 HCC patients (71 males and 9 females, mean age: 58 ± 9), 75 hepatitis B and cirrhosis (45 males and 30 females, mean age: 56 ± 8), and 99 healthy controls (70 males and 29 females, mean age: 54 ± 10) were collected from Zhongnan Hospital of Wuhan University between 2016 and 2017. All subjects were included according to the medical or pathology reports. Patients who accepted any chemotherapy or radiotherapy were not included in our study and all the included healthy controls were free of any liver disease. Plasma samples in EDTA tubes were collected within 12 h from drawn blood. Blood samples were firstly centrifuged at 2000 ***g*** for 5 min at 4°C, then the supernatants were transferred into microcentrifuge tubes and centrifuged at 12000 ***g*** for 10 min at 4°C twice to remove cellular nucleic acids completely.

Ethical approval {#sec2-2}
----------------

All subjects included in the study signed informed consents. The study was approved by the Ethics Committee of Zhongnan Hospital of Wuhan University (ethical approval number 2013059) and was done according to the Declaration of Helsinki.

RNA isolation and cDNA synthesis {#sec2-3}
--------------------------------

Trizol reagent (Invitrogen, U.S.A.) was used to extract the RNA of tissues and plasma total RNA was isolated using blood total RNA isolation kit (RP4001, BioTeke, Beijing, China) from 300 μl plasma according to the manufacturer's instructions. The concentration of RNA was measured by Nanodrop 2000 spectrophotometer (Thermo, CA, U.S.A.). The reverse-transcription reaction was performed using PrimeScript II cDNA synthesis kit with gDNA Eraser (Takara, Dalian, China). The reaction conditions for cDNA synthesis were as follows: 42°C for 2 min to remove the contaminated DNA, and then 37°C for 15 min, 85°C for 5 s.

Real-time PCR analysis {#sec2-4}
----------------------

Quantitative real-time PCR assay was performed on the Bio-Rad CFX96 (Bio-Rad Laboratories, Inc., Hercules, CA, U.S.A.) using SYBR-green I Premix EXTaq following the instructions for users. The reaction protocol was as follows: 95°C for 5 min, followed by 40 cycles of 95°C for 30 s, 63.7°C for 30 s, and 72°C for 30 s. All the primers of lncRNAs used in the present paper were listed in [Table 1](#T1){ref-type="table"} and *18S* was used as the endogenous control. Samples were analyzed in duplicate with no-template controls done at the same time.

###### Sequences of primers used in the present paper

  Name                     Sequences
  ------------ ----------- ---------------------------------
  *ZFAS1*      Sense       5′-ACGTGCAGACATCTACAACCT-3′
               Antisense   5′-TACTTCCAACACCCGCAT-3′
  *PRNCR1*     Sense       5′-CAGCAGCCGATATGATGGTATT-3′
               Antisense   5′-GGTTCTGTTGTCTGGTGATGG-3′
  *GAS5*       Sense       5′-GTGTGGCTCTGGATAGCAC-3′
               Antisense   5′-ACCCAAGCAAGTCATCCATG-3′
  *TUG1*       Sense       5′-ACAACGACTGAGCAAGCACTA -3′
               Antisense   5′-GGAGGCACAGGACATAATTCACT-3′
  *Linc-ROR*   Sense       5′-CATCCGGCGCTCAGCT-3′
               Antisense   5′-TCATGATGGCTGTATGTGCCA-3′
  *H19*        Sense       5′-GGGTCTGTTTCTTTACTTCCTCCAC-3′
               Antisense   5′-GATGTTGGGCTGATGAGGTCTGG-3′
  *18S*        Sense       5′-CAGCCACCCGAGATTGAGCA-3′
               Antisense   5′-TAGTAGCGACGGGCGGTGTG-3′

Statistical analysis {#sec2-5}
--------------------

All statistical analyses were performed using the SPSS version 17.0 (SPSS, Inc. Chicago, IL, U.S.A.) and GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, U.S.A.). Shapiro--Wilk test was used to test the normality of distribution for each dataset. Student's *t* test was operated to analyze normally distributed data, while non-normally distributed variables were tested by Kruskal--Wallis variance analysis. Receiver operating characteristic (ROC) curves were performed to evaluate the feasibility of using plasma *ZFAS1* as a diagnostic maker. All statistical tests were two-sided and *P*\<0.05 was considered statistically significant.

Results {#sec3}
=======

Selection of HCC-related lncRNAs {#sec3-1}
--------------------------------

Through searching the published literatures, six lncRNAs (*ZFAS1, PRNCR1, GAS5, TUG1, linc-ROR, H19*) which have been reported to be abnormally expressed in cancer were included in the present study. RT-qPCR was conducted to validate the expression of the six lncRNAs in 22 pairs of HCC and normal tissues. The detailed characteristics of the 22 patients are summarized in Supplementary Table S1. Results showed that *ZFAS1, TUG1, GAS5*, and *linc-ROR* were up-regulated in HCC tissues compared with paired normal tissues, while the expression levels of other lncRNAs showed no difference and therefore were eliminated in the subsequent study ([Figure 1](#F1){ref-type="fig"}). Next, we detected the four lncRNAs expression in 20 HCC and 20 control plasma. Amongst them, *TUG1* and *linc-ROR* were not detectable in plasma, *ZFAS1* was significantly up-regulated in plasma of tumor patients, while *GAS5* showed no significant changes ([Figure 2](#F2){ref-type="fig"}). Thus, we chose *ZFAS1* for our further analysis.

![*ZFAS1, TUG1, GAS5*, and *linc-ROR* were selected as the candidate lncRNAs in HCC tissue\
Increased levels of *ZFAS1, TUG1, GAS5*, and *linc-ROR* were confirmed by qRT-PCR. All data were analyzed using Student's *t* test.](bsr-38-bsr20171359-g1){#F1}

![*ZFAS1* were selected as HCC-related biomarkers in plasma\
*GAS5* showed no significant changes between plasma of HCC patients and controls, while *ZFAS1* was significantly up-regulated in plasma of HCCs. The data were analyzed using Student's *t* test.](bsr-38-bsr20171359-g2){#F2}

Analysis of stability of *ZFAS1* in whole blood and plasma {#sec3-2}
----------------------------------------------------------

Considering that stability is an important pre-requisite for the utility of biomarkers, we analyzed the stability of *ZFAS1* in whole blood and plasma. Blood samples were collected from four healthy humans (three men and one woman) and divided into three groups. Amongst the three groups, two groups were stored in whole blood form at either room temperature or 4°C and one group was stored in plasma form at −80°C. The storage conditions were as follows: room temperature for 0, 6, and 24 h; 4°C for at 0, 24 h, 3 days, and 1 week; −80°C for 0 h, 1, 2, and 4 weeks. The effects of storage conditions on the expression of *ZFAS1* were shown in [Figure 3](#F3){ref-type="fig"}. Results indicated that keeping plasma at −80°C for 1 month had no effect(s) on *ZFAS1* level. Although prolonged incubation of whole blood at room temperature for up to 24 h or at 4°C for 1 week did not change plasma *ZFAS1* levels significantly (*P*\>0.05), the plasma level of *ZFAS1* has an increase tendency when they are incubated longer than 24 h in the whole blood form, which reminds us that we should collect and handle the samples within 24 h from drawn blood.

![The effect of storage conditions on the expression level of plasma *ZFAS1*\
The data were analyzed using one-way ANOVA. No significant difference was observed in each group.](bsr-38-bsr20171359-g3){#F3}

Correlation between plasma levels of *ZFAS1* and the indexes of peripheral blood cells {#sec3-3}
--------------------------------------------------------------------------------------

Previous studies showed that some circulating lncRNAs may be derived from peripheral blood cells \[[@B16]\]. Thus, we evaluated the correlation between the plasma levels of *ZFAS1* and the indexes of peripheral blood cells in 30 HCC patients. No significant correlation between the plasma *ZFAS1* levels and indexes of whole blood were found (*P*\>0.05, [Figure 4](#F4){ref-type="fig"}).

![Correlation between plasma *ZFAS1* relative expression and the hematocytes of peripheral blood in HCC patients\
(**A**) Correlation between plasma *ZFAS1* level and WBC; (**B**) correlation between plasma *ZFAS1* level and RBC; (**C**) correlation between plasma *ZFAS1* level and PLT; (**D**) correlation between plasma *ZFAS1* level and Hb. No significant correlation between plasma *ZFAS1* and any type of peripheral hematocytes was found (*P*\>0.05). Correlations were analyzed using the Spearman correlation test.](bsr-38-bsr20171359-g4){#F4}

Validation of plasma *ZFAS1* expression level in a large scale {#sec3-4}
--------------------------------------------------------------

To validate the expression of *ZFAS1* is indeed up-regulated in HCC patients, we measured the levels of plasma *ZFAS1* in 79 control cases, 75 hepatitis B and cirrhosis patients, and 60 HCC patients by RT-qPCR. The main demographic and clinical information of the included subjects were presented in [Table 2](#T2){ref-type="table"}. No differences existed in gender, age, smoking, and alcoholism whereas a significant difference in alanine aminotransferase (ALT), aspartate aminotransferase (AST), TBIL, γ-glutamyl transferase (GGT), and glucose (GLU) amongst the groups were found.

###### Characteristics of the studied participants

  Characteristics   HCC                 Hepatitis B and cirrhosis   Control         *P*
  ----------------- ------------------- --------------------------- --------------- -----------
  Gender                                                                            0.569^1^
  Male              50                  59                          60              
  Female            10                  16                          19              
  Age                                                                               0.810^1^
  \<55              29                  35                          34              
  ≧55               31                  40                          45              
  Smoking                                                                           0.516^1^
  Negative          33                  40                          49              
  Positive          27                  35                          30              
  Alcoholism                                                                        0.604^1^
  Negative          41                  50                          48              
  Positive          19                  25                          31              
  ALT (U/l)         50 (28, 78)^4^      24 (20,38)^3^               20(16,26)       \<0.01^2^
  AST (U/l)         52 (34, 98)^4^      38 (25,48)^4^               21(20,25)       \<0.01^2^
  TBIL (μmol/l)     20 (14, 26)^3^      24 (15,34)^4^               12 (10,15)      \<0.05^2^
  GGT (U/l)         150 (68, 258)^4^    38 (20,128)^3^              21(19,37)       \<0.01^2^
  GLU (mmol/l)      5.2 (4.5, 6.1)^3^   4.8 (4.0,6.0)               4.4 (4.2,5.3)   \<0.05^2^

Data are presented as median (25 percentiles, 75 percentiles).

^1^Chi-square test.

^2^Kruskal--Wallis.

^3^*P*\<0.05.

^4^*P*\<0.01 compared with Control.

As shown in [Figure 5](#F5){ref-type="fig"}, plasma *ZFAS1* in HCC is higher than that in control group (*P*\<0.001) or in hepatitis B and cirrhosis groups (*P*\<0.001). Expression of plasma *ZFAS1* in hepatitis B and cirrhosis group was also higher than that in the healthy controls (*P*\<0.001). The association between plasma *ZFAS1* expression and clinical characteristics in HCC patients is summarized in [Table 3](#T3){ref-type="table"}. Results revealed that plasma level of *ZFAS1* was correlated to AFP, whereas no other relevance was found between *ZFAS1* level and other clinical parameters.

![*ZFAS1* expression levels in plasma amongst subgroups\
*ZFAS1* expressions in HCC patients were higher than that in hepatitis B and cirrhosis and the control groups. The data were analyzed using one-way ANOVA. \*\**P*\<0.01.](bsr-38-bsr20171359-g5){#F5}

###### Association between plasma *ZFAS1* expression and clinical characteristics in HCC patients

  Characteristics    *n*   *ZFAS1* relative expression(log)            
  ------------------ ----- ---------------------------------- -------- ---------
  Plasma\*\*                                                  −7.60    \<0.001
  HCC                60    −3.45 ± 0.51                                
  Healthy controls   79    −4.01 ± 0.35                                
  Gender                                                      −0.735   0.465
  Male               54    −3.47 ± 0.51                                
  Female             6     −3.30 ± 0.55                                
  Age                                                         −0.942   0.35
  \<55               17    −3.55 ± 0.56                                
  ≧55                43    −3.41 ± 0.49                                
  HBV DNA (IU/ml)                                             −0.704   0.485
  \<500              24    −3.49 ± 0.50                                
  ≧500               23    −3.40 ± 0.45                                
  ALT (U/l)                                                   −0.044   0.965
  \<46               29    −3.46 ± 0.53                                
  ≧46                31    −3.45 ± 0.50                                
  AST (U/l)                                                   0.488    0.628
  \<46               25    −3.42 ± 0.46                                
  ≧46                35    −3.48 ± 0.55                                
  GGT (U/l)                                                   −0.53    0.598
  \<55               20    −3.50 ± 0.48                                
  ≧55                40    −3.43 ± 0.53                                
  AFP (ng/l)\*                                                −2.91    0.006
  \<200              20    −3.64 ± 0.36                                
  ≧200               26    −3.26 ± 0.49                                
  CEA                                                         1.086    0.283
  \<5                42    −3.41 ± 0.53                                
  ≧5                 9     −3.62 ± 0.51                                

Data are shown as mean ± S.D. Since we failed to collect all characteristics of the HCC patients, the total number may not be 60. Abrreviations: CEA, carcinoembyonic antigen

\**P*\<0.05, \*\**P*\<0.001.

Diagnostic value of plasma *ZFAS1* for HCC {#sec3-5}
------------------------------------------

To assess the diagnostic value of plasma *ZFAS1* for HCC patients, ROC curves were constructed. The area under curve (AUC) of *ZFAS1* to distinguish HCC from healthy controls was 0.801 (95% CI: 0.724--0.875) at the cut-off value of −4.006 with the optical sensitivity and specificity of 55.7 and 90.0%, respectively. AFP is the most commonly used clinical index to screen HCC, so we also assessed the diagnostic value of AFP in HCC. The AUC of AFP was 0.798 (95% CI: 0.700--0.897). In our study, an association between *ZFAS1* and AFP was found, so we combined the two indexes to diagnose HCC. The AUC was high to 0.891 (95% CI: 0.829--0.953), which indicated that the combination of *ZFAS1* and AFP have a stronger diagnostic efficiency than *ZFAS1* or AFP alone ([Figure 6](#F6){ref-type="fig"}). In conclusion, our data validated that *ZFAS1* may serve as a novel diagnostic biomarker for HCC.

![Diagnostic value of plasma *ZFAS1*, serum AFP alone, and combination of these two markers for the detection of HCC\
The AUC of *ZFAS1* and AFP to distinguish HCC from healthy controls is 0.801 and 0.798, respectively. The combined AUC of these two biomarkers is 0.891. The AUC was got by performing ROC curve analysis.](bsr-38-bsr20171359-g6){#F6}

Discussion {#sec4}
==========

In the last few decades, a large number of researches have been performed to find suitable biomarkers for the diagnosis of HCC \[[@B25]\], however, the results are far from satisfactory. Clinically, AFP is the most frequently used liquid biomarker to diagnose HCC, but the sensitivity is low \[[@B26]\]. LncRNAs are a type of RNA molecule longer than 200 nts in length with no protein-coding ability \[[@B27]\]. A handful of studies have showed that lncRNAs played vital roles in many biological processes, especially in tumorigenesis. Circulating biomarkers including lncRNAs are one of the most promising markers of diagnosis since it is easy, convenient, and minimally invasive. Several circulating lncRNAs have already been identified as potential tumor markers for cancers \[[@B28],[@B29]\]. However, studies about circulating lncRNAs in diagnosis of HCC patients are few. In the present study, we aimed to explore favorable circulating lncRNAs for the diagnosis of HCC.

In the present study, six cancer-related lncRNAs were selected to explore their expression profiling in HCC tissues. Two lncRNAs were discarded due to no significant difference in HCC tissues and paired adjacent tissues. Then the remaining four lncRNAs were further measured in plasma from 20 HCC patients and 20 healthy subjects. Unfortunately, *TUG1* and *linc-ROR* were not detectable in plasma and *GAS5* was not differently expressed between HCC patients and healthy controls. Thus, *ZFAS1* was finally identified. We further explored the expression profiling of *ZFAS1* in 79 control cases, 75 hepatitis B and cirrhosis patients, and 60 HCC patients, the expression of *ZFAS1* is up-regulated from healthy, liver disease, and HCC step by step, which further validated our previous results. A study conducted by Li et al. \[[@B19]\] revealed that *ZFAS1* is up-regulated in HCC tissues and up-regulation of *ZFAS1* is correlated with poor prognosis in HCC. Our experiment is not only a validation of their study but also an extension of theirs by exploring the diagnostic role of *ZFAS1* in HCC.

To assess the diagnostic value of *ZFAS1*, ROC analysis was conducted. Results showed that AUC was 0.801 (95% CI: 0.724--0.875), suggesting that plasma *ZFAS1* could be a promising tumor marker for HCC detection. In addition, the AUC was 0.891 (95% CI: 0.829--0.953) when we use of *ZFAS1* and AFP in combination. Therefore, combing the two markers together can apparently improve the diagnostic power.

The data from our study showed that *ZFAS1* was highly expressed in plasma of HCC patients, while *TUG1* and *linc-ROR* were not detectable. Interestingly, Ma et al. \[[@B30]\] found that lncRNA *TUG1* in plasma was correlated with disease status in osteosarcoma. Isin et al. \[[@B31]\] demonstrated that the expression level of *TUG1* was up-regulated in the plasma of multiple myeloma patients compared with the healthy controls. A recent study performed by Schlosser et al. \[[@B32]\] showed that despite pre-amplification, the expression of *TUG1* and *linc-ROR* in plasma were surprisingly sporadically detectable, which is consistent with our study. It is well known that hemolysis and cellular/platelet contamination of plasma can lead to artificially elevated measurements of lncRNAs. Thus the speed and duration of centrifugation used to prepare the plasma may influence the results. Therefore, the different results between our findings and prior studies might be due to the different preparation methods and quality of plasma. In our study, the plasma was centrifuged twice at 12000 ***g*** for 10 min at 4°C to remove cells, platelets, and cell debris to the maximum extent. Besides, we collected the plasma samples within 12 h. However, the preparation of plasma specimens and collection time used in several prior studies have not been clearly elaborated.

Taken together, we clearly demonstrated that plasma levels of *ZFAS1* are higher in HCC patients than that in healthy controls and in patients with cirrhosis and hepatitis B, and the expression of *ZFAS1* is correlated to serum AFP. In addition, *ZFAS1* could be a good diagnostic marker to distinguish HCC patients from healthy controls. Nevertheless, there is still a long way to go before these findings can be used for clinic. We will prospectively confirm the usefulness of plasma *ZFAS1* in a large number of patients and report on these results in the near future.
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